ICER Eyes QALY Ratios, Budget Impacts In Methods Review
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.
You may also be interested in...
Proposed updates to group’s cost effectiveness evaluations will guide reviews during 2017-2019. Ultra-orphan drug will be assessed with different standards.
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
The Institute for Clinical and Economic Review has invited feedback on its methodology for calculating a drug's recommended price range. Industry response has been critical, but pharma can no longer afford to merely oppose value frameworks. It needs to create strategies for a world in which such frameworks are a permanent and influential part of the pricing and reimbursement landscape.